Hemoglobinopathy Treatments

Find Hemoglobinopathy Treatments

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Hemoglobinopathy.

Found 6 Approved Drugs for Hemoglobinopathy

Ferriprox

Generic Name

Deferiprone

Form: Tablet, Solution

Method of administration: Oral

FDA approval date: November 25, 2011

Classification: Iron Chelator

FERRIPROX Tablets are an iron chelator indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes.

Deferasirox

Brand Names

Deferasorox, Jadenu, Exjade

Form: Tablet, Granule

Method of administration: Oral

FDA approval date: November 30, 2005

Classification: Iron Chelator

Deferasirox granule is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.

Oxbryta

Generic Name

Voxelotor

Form: Tablet

Method of administration: Oral

FDA approval date: November 25, 2019

Classification: Hemoglobin S Polymerization Inhibitor

OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). OXBRYTA is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1 ).

Adakveo

Generic Name

Crizanlizumab

Adakveo

Generic Name

Crizanlizumab

Form: Injection

Method of administration: Intravenous

FDA approval date: April 21, 2017

Classification: Selectin Blocker

ADAKVEO ® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. ADAKVEO is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

Reblozyl

Generic Name

Luspatercept

Reblozyl

Generic Name

Luspatercept

Form: Injection

Method of administration: Subcutaneous

FDA approval date: November 08, 2019

Classification: Erythroid Maturation Agent

REBLOZYL is an erythroid maturation agent indicated for the treatment of: Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Showing 1-5 of 6

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances